ascopubs.org

SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.

Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy. This is an ASCO Meeting Abstract from ...
Nasdaq

Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer

SI-B001 is a bispecific antibody designed with the proprietary platform technology developed by Baili and SystImmune. It can bind to EGFR and HER3, and simultaneously inhibits the ligand induced ...
ascopubs.org

Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck ...

Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of ...
Hypebeast

G-SHOCK Launches the G-B001 With Double Bezels

G-SHOCK has announced a new model to its ever-expansive collection of shock-resistant watches — the G-B001 with a playful double bezel Capsule Tough construction. While the new watch inherits the ...
thaipr.net

Casio to Release G-SHOCK with Integrated Bezel and Band Construction

Casio Computer Co., Ltd. announced today the release of the latest new G-SHOCK shock-resistant watches – four GA-B001 and GA-B001G models featuring an all-new integrated bezel and band construction.